# Nong Yang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nong-yang-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,307 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 18 |
| i10-index | 25 |
| Last Known Institution | Central South University |
| OpenAlex ID | https://openalex.org/A5115597503 |
| Works | 71 |

## Researcher papers

- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study](https://scholariq.org/papers/furmonertinib-ast2818-versus-gefitinib-as-first-line-therapy-for-chinese/)
- [Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial](https://scholariq.org/papers/tislelizumab-plus-platinum-and-etoposide-versus-placebo-plus-platinum-and/)
- [Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study](https://scholariq.org/papers/central-nervous-system-efficacy-of-furmonertinib-ast2818-versus-gefitinib-as/)
- [40Ar/39Ar dating of shear deformation of the Xianshuihe fault zone in west Sichuan and its tectonic significance](https://scholariq.org/papers/40ar-39ar-dating-of-shear-deformation-of-the-xianshuihe-fault-zone-in-west/)
- [Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial](https://scholariq.org/papers/cadonilimab-with-chemotherapy-in-her2-negative-gastric-or-gastroesophageal/)
- [Active Faulting Pattern, Present‐day Tectonic Stress Field and Block Kinematics in the East Tibetan Plateau](https://scholariq.org/papers/active-faulting-pattern-present-day-tectonic-stress-field-and-block-kinematics/)
- [Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China](https://scholariq.org/papers/lorlatinib-for-previously-treated-alk-positive-advanced-nsclc-primary-efficacy/)
- [Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments](https://scholariq.org/papers/changes-of-tumor-microenvironment-in-non-small-cell-lung-cancer-after-tki/)
- [Chinese expert consensus on the diagnosis and treatment of thymic epithelial tumors](https://scholariq.org/papers/chinese-expert-consensus-on-the-diagnosis-and-treatment-of-thymic-epithelial/)
- [The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer](https://scholariq.org/papers/the-clinicopathologic-of-pulmonary-adenocarcinoma-transformation-to-small-cell/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Quinazolinone synthesis and applications](https://scholariq.org/topics/quinazolinone-synthesis-and-applications/)

## Researcher university

- [Central South University](https://scholariq.org/institutions/central-south-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.